Correction

Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV

M Victoria Flores1*, Timothy P Hickling2, Sasha Sreckovic3, Mark D Fidock4, Nigel Horscroft1, Madan Katragadda5, Boris Savic4, Jaiessh Rawal2, Oona E Delpuech-Adams1, Nicola Robas4, Thomas Corey4, Linda Nelms5, Michael Lawton6, John Marcek6, Makeida Stubbs6, Michael Westby1, Giuseppe Ciaramella7

1Antivirals Group, Pfizer Inc., Sandwich, UK
2Translational Research, Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Sandwich, UK
3Drug Safety Research and Development, Pfizer Inc., Sandwich, UK
4Quantitative Biomarkers Group, Pfizer Inc., Sandwich, UK
5BioTherapeutics Research, Pfizer Inc., Cambridge, MA, USA
6Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA
7BioTherapeutics Research, Pfizer Inc., Sandwich, UK

*Corresponding author e-mail: v.flores@btinternet.com

The publisher would like to report an error that appeared in a recently published article [1]. The final sentence of the Conclusions of the abstract should read ‘The potency and pharmacokinetic properties of the molecule are consistent with dosing at least every two weeks with the potential for monthly dosing’ and not ‘at least twice daily’ as presented in the original. The publishers apologize for this mistake.

References


Accepted 23 April 2012; published online 24 April 2012